



HÉMA-QUÉBEC

Produits sanguins
Cellules souches
Tissus humains



Saint-Laurent, May 25th, 2015

BY EMAIL



OBJET: Your request for access to information

Dear [redacted],

Following your request for access to information on April 28th, 2015, you will find hereunder the requested information regarding the COAGULATION FACTORS RECOMBINANT FACTOR VIII AND FACTOR IX - REQUEST FOR PROPOSALS - AO2014-011.

The prices are for terms of three years for Factor VIII and two years for Factor IX, excluding the options that can be exercisable by Héma-Québec.

FACTOR VIII

Bidder's name	Total Price for selected scenario Xyntha 80-88% 3 years	Non-Compliance bid : bidder's name and specifics of non compliance
Baxter - Advate	[redacted]	N/A
Bayer - Cogenate	[redacted]	N/A
Biogen – Eloctate	[redacted]	N/A
Novo-Nordisk - Zonovate	[redacted]	Did not pass quality evaluation
Octapharma - Newiq	[redacted]	N/A
CSL Behring	[redacted]	Price disclosure in bid documents
Pfizer - Xyntha	[redacted]	N/A

FACTOR IX

Bidder's name	Unit Price for selected scenario Benefix 100% 2 years	Non-Compliance bid : bidder's name and specifics of non compliance
Baxter - Rixubix	N/Q	Decided not to quote
Biogen Alprolix		N/A
Pfizer - BeneFix		N/A

I trust the above information is satisfactory.

Sincerely yours,

ORIGINAL SIGNÉ

Isabelle Allard, conseillère juridique
 Responsable de l'accès aux documents et de
 la protection des renseignements personnels
 Tél. : (514) 832-5000 poste 5240
 Courriel : isabelle.allard@hema-quebec.qc.ca

IA/iau